Estimates indicate that at least 30,000 LSCD patients in the US are actively being managed by an eye care professional. The company plans to initiate clinical trials in the first half of 2027. The A round was for early clinical studies that often have more risk associated with them. The capital will also support the planned pivotal program and enable pre-commercialization activities – effectively financing Claris through Phase III development. “The A round was for early clinical studies that often have more risk associated with them.